[
  {
    "ts": null,
    "headline": "PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership",
    "summary": "PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, today announced the successful closing of $11 million in funding and two key leadership hires. This latest round of funding was led by Eventide Asset Management (\"Eventide\"), Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This fund",
    "url": "https://finnhub.io/api/news?id=2b5fe3652c0b6a9313ce88f23338a98d74377a6966c66871ea99e755f787c3d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750244220,
      "headline": "PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership",
      "id": 135353195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, today announced the successful closing of $11 million in funding and two key leadership hires. This latest round of funding was led by Eventide Asset Management (\"Eventide\"), Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This fund",
      "url": "https://finnhub.io/api/news?id=2b5fe3652c0b6a9313ce88f23338a98d74377a6966c66871ea99e755f787c3d2"
    }
  }
]